Cancer Communications
CANCER COMMUN
影响因子:24.9
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:PEOPLES R CHINA
出版社:BioMed Central
发刊时间:2015
发刊频率:
收录数据库:SCIE/Scopus收录/DOAJ开放期刊
ISSN:2523-3548

中科院2-4区医学SCI协投:

影响因子0-3分,2-4个月确保录用

医学全方向沾边就收,无需大修

微信扫码提交文章

期刊介绍
Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
《 癌症 通讯 》 是 一 本 开放 获取 、 同行 评审 的 在线 期刊 , 涵盖 基础 、 临床 和 转化 癌症 研究 。该 杂志 欢迎 有关 临床 试验 , 流行 病学 , 分子 和 细胞 生物 学 和 遗传 学 的 投稿 。
年发文量 49
国人发稿量 -
国人发文占比 -
自引率 -
平均录取率-
平均审稿周期 4 Weeks
版面费 -
偏重研究方向 Biochemistry, Genetics and Molecular Biology-Cancer Research
期刊官网 https://www.springer.com/journal/40880
投稿链接 https://www.editorialmanager.com/CHJC
期刊高被引文献
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0349-9
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0361-0
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-018-0346-4
Dual prognostic role of 2-oxoglutarate-dependent oxygenases in ten cancer types: implications for cell cycle regulation and cell adhesion maintenance
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0369-5
Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0365-9
Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0356-x
PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0376-6
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0383-7
National trend of gastric cancer mortality in China (2003–2015): a population-based study
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0372-x
Targeting mitochondria as an anticancer strategy
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0412-6
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0354-z
Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0362-z
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0351-2
Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0410-8
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0359-7
Pathological transition as the arising mechanism for drug resistance in lung cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0402-8
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0385-5
Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0417-1
Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0415-3
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0418-0
Retrieved lymph nodes from different anatomic groups in gastric cancer: a proposed optimal number, comparison with other nodal classification strategies and its impact on prognosis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0394-4
New frontiers in proton therapy: applications in cancers
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0407-3
Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0363-y
Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0398-0
Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0401-9
A novel role of LncRNA in regulating tumor metabolism and angiogenesis under hypoxia
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0348-x
Disrupting redox stabilizer: a novel therapeutic strategy for colorectal cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0355-y
Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0382-8
Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0386-4
Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0350-3
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0424-2
Clinical outcomes of angiosarcoma: a single institution experience
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0389-1
Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0381-9
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0375-7
Primary intrathoracic liposarcoma: a clinical analysis of 31 cases
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0358-8
Nuclear glycogenolysis modulates histone acetylation: a novel mechanism of epigenetic regulation in cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0420-6
Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0378-4
Modelling the probability of erroneous negative lymph node staging in patients with colon cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0377-5
S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0408-2
Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0403-7
Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0400-x
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0409-1
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0395-3
Is cancer-related death associated with circadian rhythm?
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0373-9
Radiation pneumonitis complicated by Pneumocystis carinii in patients with thoracic neoplasia: a clinical analysis of 7 cases
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0392-6
In pursuit of a flawless aphrodite: paving the way to scarless oncoplastic breast surgery
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0422-4
Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0396-2
Skull bone tumor: a review of clinicopathological and neuroimaging characteristics of 426 cases at a single center
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0353-0
CD137 expression in cancer cells: regulation and significance
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0419-z
Correction to: Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0352-1
质量指标占比
研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
64.52%---
相关指数
影响因子
影响因子
年发文量
自引率
Cite Score
预警情况 查看说明
时间 预警情况
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2021年01月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》
JCR分区 WOS分区等级:Q1区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
ONCOLOGY
Q1
中科院分区 查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2023年12月最新升级版
医学1区
ONCOLOGY
肿瘤学
1区
2022年12月升级版
医学2区
ONCOLOGY
肿瘤学
2区
2021年12月基础版
医学1区
ONCOLOGY
肿瘤学
1区
2021年12月升级版
医学1区
ONCOLOGY
肿瘤学
1区
2020年12月旧升级版
医学1区
ONCOLOGY
肿瘤学
2区